RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway
This article was originally published in PharmAsia News
Executive Summary
TOKYO - An executive from Massachusetts-based biotech Alnylam says its RNAi alliances with Takeda and Kyowa Hakko Kirin are well underway
You may also be interested in...
Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)
Attend any industry conference these days, and a general theme arises that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage projects, could impact long-term future development of emerging biotechnologies.
Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)
Attend any industry conference these days, and a general theme arises that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage projects, could impact long-term future development of emerging biotechnologies.
Corporate Venture Capital’s Role In Developing Next-Generation Biologics: An Interview With Takeda Research Investment’s Graeme Martin (part 2 of 2)
With private-equity investments in early-stage financing gone, corporate venture needs to support these opportunities, “because if you don’t, the biotechnology industry is going to disappear. It’s just going to dry up,” Martin maintains.